Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

¡¾ÅÌ»õ¡¿µ¥õ£¸ÊÓÍõ¥Ã¸£¨MAGL£©ÒÖÖÆ¼ÁµÄÑо¿Ï£Íû

2018-11-30
|
»á¼ûÁ¿£º

¡¾ÅÌ»õ¡¿µ¥õ£¸ÊÓÍõ¥Ã¸£¨MAGL£©ÒÖÖÆ¼ÁµÄÑо¿Ï£Íû

µ¥õ£¸ÊÓÍõ¥Ã¸£¨Monoacylglycerol lipase,MAGL£©ÊÇÒ»ÖÖË¿°±ËáË®½âø[1]£¬£¬£¬£¬£¬£¬²»µ«ÄÜÔÚÖ¬ÖÊ´úлÖн«Èýõ£¸ÊÓÍÆÊÎöΪÓÎÀëÖ¬·¾ËáºÍ¸ÊÓÍ£¬£¬£¬£¬£¬£¬Îª»úÌ幩ÄÜ£¬£¬£¬£¬£¬£¬²¢ÇÒÄܹ»Ë®½â2-»¨ÉúËÄÏ©Ëá¸ÊÓÍõ¥£¨2-AG£©£¬£¬£¬£¬£¬£¬µ÷ÀíÌåÄÚ´óÂéËØÏµÍ³ÐźÅתµ¼¡£¡£¡£2-»¨ÉúËÄÏ©Ëá¸ÊÓÍõ¥ÊÇÄÚÔ´ÐÔ´óÂéËØÏµÍ³×é³É²¿·Ö£¬£¬£¬£¬£¬£¬¶øÄÚÔ´ÐÔ´óÂéËØÓë»úÌåÄÔËðÉ˱£» £»£»£»£»¤£¬£¬£¬£¬£¬£¬ÃâÒßÓ¦´ð£¬£¬£¬£¬£¬£¬Ñ×Ö¢·´Ó¦µÈÓйØ£» £»£»£»£»×îеÄÑо¿Ö¸³ö£¬£¬£¬£¬£¬£¬ÄÚÔ´ÐÔ´óÂéËØÏµÍ³ÔÚ²¿·ÖÖ×ÁöÖпÉÒÔÒÖÖÆ°©Ï¸°ûÔöÖ³£¬£¬£¬£¬£¬£¬ÓÕµ¼Ö×Áöϸ°ûµòÍö£¬£¬£¬£¬£¬£¬ÔÚÖ×ÁöÉú³¤ÖÐÓ°ÏìÖ×ÁöѪ¹ÜÌìÉú¡£¡£¡£

µ¥õ£¸ÊÓÍõ¥Ã¸Ð¡°Ù¿Æ

µ¥õ£¸ÊÓÍõ¥Ã¸ÊÇË¿°±ËáË®½âø¼Ò×åÖеÄÒ»Ô±£¬£¬£¬£¬£¬£¬Ë¿°±ËáË®½âø¼Ò×å°üÀ¨250ÖÖ²î±ðµÄÂѰ×ø£¬£¬£¬£¬£¬£¬ÊÇÔ­ºËºÍÕæºËϸ°ûÖÐ×îÖØ´óµÄø¼Ò×åÖ®Ò»¡£¡£¡£Ë¿°±ËáË®½âøµÄ¼¤»îÊÇͨ¹ý»îÐÔÖÐÐÄÒ»×é°±»ùËá²Ð»ùת±äʵÏֵ쬣¬£¬£¬£¬£¬²¢ÔÚ¶àÖÖÈËÌåÐÄÀíÀú³ÌºÍ¼²²¡ÖÐÆðµ½Òªº¦×÷Ó㬣¬£¬£¬£¬£¬ÌØÊâÊÇÔÚÏû»¯£¬£¬£¬£¬£¬£¬ÄýѪºÍ²¹ÏµÒ»Çз½Ãæ¡£¡£¡£ÓÉÓÚË¿°±ËáË®½âøµÄÖ÷ÒªÑо¿¼ÛֵʹµÃ´ó×ڵIJî±ð½á¹¹µÄË¿°±ËáË®½âøÒÖÖÆ¼Á±»Ñз¢³öÀ´£¬£¬£¬£¬£¬£¬ÕâЩÒÖÖÆ¼ÁÒ»·½Ãæ¿É×÷ΪDZÔÚµÄÖÎÁÆÒ©Î£¬£¬£¬£¬£¬ÁíÒ»·½Ãæ¿É×÷ΪÓмÛÖµµÄС·Ö×Ó̽ÕëÀ´Ñо¿Ë¿°±ËáË®½âøµÄ¹¦Ð§¡£¡£¡£¿ÉÊÇ£¬£¬£¬£¬£¬£¬Ö»¹ÜÓжà¸öÏȵ¼½á¹¹±»·¢Ã÷¿ÉÒÔÒÖÖÆË¿°±ËáË®½âø£¬£¬£¬£¬£¬£¬È´ÒÀ¾Éȱ·¦¸ß»îÐÔ¡¢¸ßÑ¡ÔñÐÔµÄÒÖÖÆ¼Á¡£¡£¡£

Ö»¹ÜË¿°±ËáË®½âøÔڽṹÉϱ£´æ¸ß¶È²î±ðÐÔ£¬£¬£¬£¬£¬£¬µ«ËüÃǵĴ߻¯»úÖÆÈ´ÊÇÏàͬµÄ£¬£¬£¬£¬£¬£¬ÏêϸµÄÀú³ÌÊÇ£º

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

µ¥õ£¸ÊÓÍõ¥Ã¸µÄÌåÄÚµ÷Àí×÷ÓÃ

1£¬£¬£¬£¬£¬£¬MAGLÓëÖ¬ÖÊ´úÐ»ÍøÂçÇ×½üÏà¹Ø£¬£¬£¬£¬£¬£¬MAGL¿Éͨ¹ýMAGL-FFA£¨ÓÎÀëÖ¬·¾Ëᣩͨ·µ÷ÀíÖ¬·¾Ëá´úÐ»ÍøÂç¡£¡£¡£

2£¬£¬£¬£¬£¬£¬ÌåÄÚÑо¿Åú×¢£¬£¬£¬£¬£¬£¬MAGLµÄÒÖÖÆ¼ÁÔÚСÊóÑ×Ö¢ºÍÉñ¾­ÐÔÌÛÍ´Ä£×ÓÖÐʩչÒÖÖÆ´óÂéËØ¢ñÐÍÊÜÌ壨CB1£©µÄ×÷Óᣡ£¡£

3£¬£¬£¬£¬£¬£¬2012Ä꣬£¬£¬£¬£¬£¬ÔÚ°¢¶û´Äº£Ä¬Êϲ¡Ð¡ÊóÄ£×ÓÖÐ֤ʵ£ºÒÖÖÆMAGLÄܹ»ÏÔÖø½µµÍµí·ÛÑùÉñ¾­²¡Àí£¬£¬£¬£¬£¬£¬ïÔÌ­Éñ¾­Ñ×Ö¢ºÍÍË»¯£¬£¬£¬£¬£¬£¬¸ÄÉÆÍ»´¥ºÍÈÏÖª¹¦Ð§¡£¡£¡£

4£¬£¬£¬£¬£¬£¬ÁíÍâһЩÑо¿·¢Ã÷MAGLÒÖÖÆ¼Á¶Ô·ÇçÞÌ忹Ñ×Ò©ÒýÆðµÄθ³öѪģ×ÓºÍÑ×Ö¢ÐÔ³¦²¡Ä£×ÓÆðµ½Á¼ÐÔ×÷Óᣡ£¡£

¸Î°©Êdz£¼ûµÄ¸ÎÔàÔ­·¢ÐÔ¶ñÐÔÖ×Áö£¬£¬£¬£¬£¬£¬ÆäÖÂËÀÂʾÓÊÀ½çµÚÈý룬£¬£¬£¬£¬£¬²¢ÔÚÊÀ½ç¹æÄ£ÄÚ·ºÆðÖðÄêÉÏÉýÇ÷ÊÆ¡£¡£¡£ÉîÈëÑо¿¸Î°©µÄ·¢²¡»úÖÆ£¬£¬£¬£¬£¬£¬Ñ°ÕҸΰ©×éÖ¯ÖÐÒì³£±í´ïµÄ»ùÒò»òµ°º×·¢Ã÷£º·ÊÅÖºÍÖ¬ÖÊ´úлÔÓÂÒÊǸΰ©±¬·¢µÄ¸ßΣÒòËØ£¬£¬£¬£¬£¬£¬¶ø·ÊÅÖºÍÖ¬ÖÊ´úлÔÓÂÒÓÖÓëµ¥õ£¸ÊÓÍõ¥Ã¸Ç×½üÏà¹Ø¡£¡£¡£

MAGLÔÚ¶ñÐÔÐþÉ«ËØÁö¡¢ÈéÏÙ°©¼°Âѳ²°©Ï¸°ûÖÐÏÔ×ÅÉý¸ß£¬£¬£¬£¬£¬£¬MAGsˮƽϽµ£¬£¬£¬£¬£¬£¬ÓÎÀëÖ¬·¾ËᣨFFAs£©Ë®Æ½ÉÏÉý¡£¡£¡£Í¨¹ýMAGL-FFAͨ·£¬£¬£¬£¬£¬£¬¶ñÐÔÖ×Áöϸ°û¿ÉÒÔÒýÆðÈÜѪÁ×Ö¬ËᣨLPA£©¡¢ÈÜѪÁ×Ö¬õ£µ¨¼î£¨LPC£©¡¢ÈÜѪÁ×Ö¬ËáÒÒ´¼°·£¨LPE£©¡¢Ç°ÏßÏÙËØE2£¨PGE2£©µÈһϵÁÐÖ¬ÖÊÐźŷÖ×ÓˮƽÉÏÉý¡£¡£¡£ÆäÖÐPGE2µÄÉÏÉý£¬£¬£¬£¬£¬£¬¿ÉʹÏÂÓεÄTyr397λµãÁ×Ëữ£¬£¬£¬£¬£¬£¬È»ºóÓëÂѰ×ÊÜÌåºÍÉú³¤Òò×ÓÁ¬Ïµ£¬£¬£¬£¬£¬£¬Ôö½øÏ¸°ûµÄ×ªÒÆºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¶øÈÜѪÁ×Ö¬ËᣨLPA£©Äܼ¤»î¶àÖÖGÂѰ׿ÁªÊÜÌ壬£¬£¬£¬£¬£¬Í¨¹ý²î±ðµÄ¿¹µòÍöÐźÅͨ·£¬£¬£¬£¬£¬£¬Ôö½øÖ×Áöϸ°ûµÄ´æ»îºÍÔöÖ³¡£¡£¡£

²¿·ÖÒѱ¨µÀµÄMAGLÒÖÖÆ¼Á

ÔÚÒÑÍùµÄ10ÄêÀ£¬£¬£¬£¬£¬Ò»Ö±ÔÚÆð¾¢¿ª·¢ÐÂÐÍMAGLÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬ÏÖÒѱ¨µÀµÄС·Ö×ÓÀàMAGLÒÖÖÆ¼ÁԼĪÓÐ20¸ö£¬£¬£¬£¬£¬£¬Ö÷Òª°üÀ¨MAGLÄÚÔ´ÐÔµ×Îï2-AGµÄÄ£ÄâÀàËÆÎïºÍÖÖÖÖ´Ó»¯ºÏÎï¿âÖÐɸѡ»ñµÃ²¢Ë¢ÐµĻ¯ºÏÎï¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

LongµÈ[2]ͨ¹ý»ùÓÚ»îÐÔµÄÂÑ°×Æ×ѧÑо¿ÒªÁ죨activity-basedproteinprofiling£¬£¬£¬£¬£¬£¬ABPP£©£¬£¬£¬£¬£¬£¬·¢Ã÷ßßर±»ù¼×Ëáõ¥À໯ºÏÎïJZL184£¬£¬£¬£¬£¬£¬ÆäÔÚµÍŨ¶ÈÏÂÄÜÑ¡ÔñÐÔÒÖÖÆÐ¡ÊóÄÔÂѰ×ÖÐMAGLµÄ»îÐÔ¡£¡£¡£ÔÚÓÃJZL184´¦Öóͷ£Ð¡Êóºó£¬£¬£¬£¬£¬£¬2-»¨ÉúËÄÏ©Ëá¸ÊÓÍõ¥£¨2-AG£©µÄ±í´ïˮƽÏÔÖøÌá¸ß5-10±¶¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

ΪÁ˽øÒ»²½µÄÌá¸ßÒÖÖÆ¼ÁµÄÑ¡ÔñÐÔ£¬£¬£¬£¬£¬£¬ChangµÈ[3]Éè¼ÆÁË»¯ºÏÎïKML29£¬£¬£¬£¬£¬£¬ABPPʵÑéÅú×¢KML29ÔÚ»îÌå¼°ÀëÌåÌõ¼þϾùÄÜÑ¡ÔñÐÔÒÖÖÆMAGLµÄ»îÐÔ¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

NiphakisµÈ[4]·¢Ã÷¶¡¶þõ£Ñǰ·»ù¼×Ëáõ¥À໯ºÏÎïMJN110£¬£¬£¬£¬£¬£¬ÆäͬÑù¿ÉÒÔÔÚ»îÌå¼°ÀëÌåÌõ¼þϸßЧ¡¢¸ßÑ¡ÔñÐÔÒÖÖÆMAGLµÄ»îÐÔ¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

2013Ä꣬£¬£¬£¬£¬£¬AaltonenµÈ[5]·¢Ã÷ßßà¤ÈýßòëåÀ໯ºÏÎïJJKK-048Äܳ¬¸ßЧÒÖÖÆMAGLµÄ»îÐÔ£¬£¬£¬£¬£¬£¬ÆäIC50ֵСÓÚ0.4Nm£¬£¬£¬£¬£¬£¬Í¬Ê±ÔÚABPPʵÑé·¢Ã÷£ºJJKK-048¶ÔMAGL¾ßÓм«¸ßµÄÑ¡ÔñÐÔ¡£¡£¡£

ÔÚС·Ö×ÓÒÖÖÆ¼ÁÒ»Ö±±»Ñо¿¿ª·¢Àú³ÌÖУ¬£¬£¬£¬£¬£¬×ÔÈ»²úÆ·Ò»Ö±ÒÔÀ´¶¼ÊÇÆäÖ÷ҪȪԴ֮һ£¬£¬£¬£¬£¬£¬Òѱ¨µÀµÄ×ÔÈ»MAGLÒÖÖÆ¼Á°üÀ¨±âËÜÌÙËØ£¬£¬£¬£¬£¬£¬´óꪶþÏ©´¼ºÍµ¤²Îͪ¢òA3Àà½á¹¹£¬£¬£¬£¬£¬£¬¿ÉÊÇÕâÈýÀà½á¹¹¾ùÎªÝÆÀ໯ºÏÎ£¬£¬£¬£¬£¬ÇÒ¶¼¾ßÓнϸߵÄÇ×Ö¬ÐÔ£¬£¬£¬£¬£¬£¬ÕâÏÞÖÆÁ˶ÔÕâЩ»¯ºÏÎï½øÒ»²½¾ÙÐÐÒ©ÎﻯѧˢеĿÉÄÜÐÔ£¬£¬£¬£¬£¬£¬Òò´ËѰÕÒÐÂÐÍ×ÔÈ»»ò·Ç×ÔÈ»MAGLÒÖÖÆ¼ÁÈÔÊǸÃÑо¿ÁìÓòµÄÈÈÃÅ¡£¡£¡£

MAGLÒÖÖÆ¼ÁµÄ½üÆÚÑо¿ÈÈÃÅ

Ö»¹ÜÒѾ­Óжà¸öMAGLÒÖÖÆ¼ÁÒѾ­±»±¨µÀ£¬£¬£¬£¬£¬£¬¿ÉÊǸ߻îÐÔ¡¢¸ßÑ¡ÔñÐÔ¡¢¾ßÓгÉÒ©ÐÔµÄMAGLÒÖÖÆ¼ÁÒÀ¾ÉÈ´·¦¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

µ¥õ£» £»£»£»£»ù¸ÊÓÍÖ¬·¾Ã¸(MGLL»òMAGL)Êǵ÷ÀíÄÚÔ´ÐÔ´óÂéËØºÍÀà¶þÊ®´¼ÀàÐźÅͨ·µÄÒ»¸öÁÙ½çµã£¬£¬£¬£¬£¬£¬´Ó¶øÎªÉñ¾­ºÍÉñ¾­ÍËÐÐÐÔ¼²²¡ÌṩеÄÖÎÁÆÊ±»ú¡£¡£¡£CisarµÈÈËÔÚÎÄÏ×[6]ÖÐÌá³öÁËÒÔÁù·úÒì±û»ù°±»ù¼×Ëáõ¥Îª»ù´¡µÄMGLL²»¿ÉÄæÒÖÖÆ¼ÁµÄ¿ª·¢¼°ÓÅ»¯£¬£¬£¬£¬£¬£¬×îÖÕ»ñµÃ¸ßЧ¡¢Ñ¡ÔñÐԺͿڷþÓÐÓõÄABX-1431¡£¡£¡£ABX-1431ÔÚÒ»ÆÚÁÙ´²Ñо¿ÖÐÄÍÊÜÐÔÓÅÒ죬£¬£¬£¬£¬£¬Çå¾²ÐԸߣ¬£¬£¬£¬£¬£¬²¢ÔÚ»¼ÓÐÉñ¾­ÏµÍ³¼²²¡µÄ»¼ÕßÖÐÏÔʾÁË½ÏºÃµÄÆðԴЧ¹û¡£¡£¡£Ñо¿µÄÊý¾ÝÅú×¢£¬£¬£¬£¬£¬£¬ËüÊÇÖÎÁƳÉÈËGilles de la Tourette×ÛºÏÖ¢µÄDZÔÚÒ©Îï¡£¡£¡£ABX-1431ÏÖÔÚÒѾ­ÀֳɵØÍê³ÉÁËÒ»ÆÚÁÙ´²ÊÔÑ飬£¬£¬£¬£¬£¬Õý½ø×ÅÃÔ¾­Õϰ­µÄÁÙ´²Ñо¿µÄµÚ¶þ½×¶Î£¬£¬£¬£¬£¬£¬²¢¶ÔÆäËû˳Ӧ֢£¬£¬£¬£¬£¬£¬ÈçÊÓÉñ¾­ÇÊÑ׺Ͷ෢ÐÔÓ²»¯¾ÙÐÐÁÙ´²ÊÔÑé¡£¡£¡£

 ABX-1431µÄºÏ³Éõè¾¶£º

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

ÔÚJumpei AidaµÈÈË[7]½üÆÚ½ÒÏþµÄÎÄÏ×ÖУ¬£¬£¬£¬£¬£¬ÒÔßßàºßÁ¿©à¤»¯ºÏÎï2bΪ»ù´¡£¡£¡£¬£¬£¬£¬£¬£¬Í¨¹ýË¢ÐÂÉè¼Æ£¬£¬£¬£¬£¬£¬ÔöÇ¿ßßàºßÁ¿©à¤ºË¼°ÆäÈ¡´ú»ùÓëMAGLøµÄÏ໥×÷Ó㬣¬£¬£¬£¬£¬ÕÒµ½ÁËÒ»ÖÖÓÐÓÃÇÒ¿ÉÄæµÄMAGLÒÖÖÆ¼Á»¯ºÏÎï(R)-3t¡£¡£¡£ÔÚ¸øÐ¡Êó¿Ú·þ(R)-3tºó£¬£¬£¬£¬£¬£¬¿ÉÉý¸ßСÊóµÄ2-»¨ÉúËÄÏ©Ëá¸ÊÓÍõ¥£¨2-AG£©Ë®Æ½¡£¡£¡£Óɴ˿ɼû(R)-3tÊÇÒ»ÖÖ¿ÉÄܳÉÒ©µÄµ¥õ£¸ÊÓÍõ¥Ã¸µÄС·Ö×ÓÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬ÖµµÃ½øÒ»²½µÄ̽ÌÖ¡£¡£¡£

ÃÀ¸ß÷¡¤MGM(ÖйúÓÎ)¹ÙÍøÕýÍø

MAGL²»¿ÉÄæ×ªµÄÒÖÖÆ¼ÁÔÚÖØ¸´¸øÒ©ºó»áʹСÊ󱬷¢½»Ö¯ÄÍÊÜÐÔ¡£¡£¡£ÂýÐÔMAGL×èÖÍ»¹»áÒýÆðÐÄÀíÒÀÀµ£¬£¬£¬£¬£¬£¬Ëðº¦ÄÚÔ´ÐÔ´óÂéËØÍ»´¥¿ÉËÜÐÔ¡£¡£¡£¶ø¿ÉÄæµÄMAGLÒÖÖÆ¼Á¿ÉÒÔÒÖÖÆÃ¸»îÐÔµÄͬʱ¼á³Öendocan-nabinoidϵͳÍêÕû¡£¡£¡£ÔÚÕâЩÎÊÌâ»ù´¡ÉÏ£¬£¬£¬£¬£¬£¬¿ÉÄæÒÖÖÆ¼ÁµÄÓ¦ÓÿÉÄÜ»áÊÇMAGLÒÖÖÆ¼ÁÁìÓòµÄÒ»¸öÖ÷ÒªÉú³¤¡£¡£¡£

²Î¿¼ÎÄÏ×£º

1,Gil-Ordonez, A. Martin-Fontecha, M. Ortega-Gutierrez, S. Lopez-Rodriguez, M. L.Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochem.Pharmacol. 2018.

2,Long J Z, Li W, Booker L et al. Selective blockade of 2-arachidonoylglycerolhydrolysis produces cannabionoid behavioral effects. Nature Chemical Biology,2009,5 (1):37-44.

3,Chang JW1, Niphakis MJ, Lum KM et al. Highly selective inhibitors ofmonoacylglycerol lipase bearing a reactive group that is bioisosteric withendocannabinoid substrates. Chem Biol. 2012 May 25;9(5):579-88.

4,Niphakis MJ, Cognetta AB, Chang JW et al. Evaluation of NHS carbamates as apotent and selective class of endocannabinoid hydrolase inhibitors. ACS ChemNeurosci. 2013 Sep 18;4(9):1322-32.

5,Aaltonen N1, Savinainen JR, Ribas CR et al. Piperazine and piperidine triazoleureas as ultrapotent and highly selective inhibitors of monoacylglycerollipase. Chem Biol. 2013 Mar 21;20(3):379-90.

6,Justin S. Cisar, Olivia D. Weber, Jason R. Clapper et al. Ezekowitz, Gary P.O¡¯Neill?, and Cheryl A. Grice. Identification of ABX-1431, a SelectiveInhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment ofNeurological Disorders. J. Med. Chem. 2018, 61, 20, 9062-9084.

7,JumpeiAida, Makoto Fushimi, Tomokazu Kusumoto et al. Design, Synthesis, andEvaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of ReversibleMonoacylglycerol Lipase Inhibitors. J. Med. Chem. 2018, 61, 20, 9205-9217.

ÁªÏµÃÀ¸ß÷£º
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©
Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿